A Look into Post-marketing Pharmacovigilance and Medical Information Industry……Deep Analysis…..
Global post-marketing
pharmacovigilance and medical information market is expected to reach USD 5.3 Billion by 2022, according to a new report by Grand View
Research, Inc. Increasing prevalence of Adverse Drug Reactions (ADRs) coupled
with incorporation of advanced ADR reporting tools is responsible for the
overall growth of the post-marketing pharmacovigilance and medical information
market. Increased drug consumption can be attributed to rising prevalence of
chronic diseases such as tuberculosis that involve multiple drug regimes.
Rising government initiatives for
improvement of pharmacovigilance services and maintenance of medical databases
are also responsible for inducing overall growth of post-marketing
pharmacovigilance and medical information market. For instance, in December
2015, the USAID Systems for Improved Access to Pharmaceuticals and Services
(SIAPS) launched PViMS tool to improve drug safety monitoring in low and middle
income countries by helping clinicians, researchers, and regulatory authorities
to collect, analyze, and monitor ADRs.
Post-marketing
pharmacovigilance and medical information market is catered by players such
Accenture Plc, Clinquest Group, B.V., Cognizant Technology Solutions Corp.,
Covance Inc., iMEDGlobal Corp., inVentiv Health Clinical, Parexel International
Corporation, Pharmaceutical Product Development Inc, PRA Health Sciences,
Quintiles Transnational Corporation, F. Hoffmann-La Roche Ltd. Sanofi,
Synowledge, Wipro Ltd., ArisGlobal and Ergomed.
Market is highly competitive in nature and manufacturers are
focusing on strategies such as merger & acquisition, collaborative
agreements and new product development for sustaining the competition and gain
more industry share.Presence of a competitive environment has led to the
streamlining of R&D, manufacturing operations, medical writing, pharmacovigilance
and clinical data management. Manufacturers are rapidly adhering to outsourcing
as a viable cost curbing tool.
To Request Sample Copy of this report, click the link:
Further key findings
from the study suggest:
·
Spontaneous reporting dominated the
post-marketing pharmacovigilance market in terms of revenue share as of 2014
and accounted for over 30.0% of market owing to wide usage in reporting of
unknown and suspected ADRs. Preference of healthcare professionals and
researchers towards this method is also responsible for the overall growth of
this segment.
·
Cohort event monitoring is anticipated to
be the fastest growing in post-marketing pharmacovigilance owing to application
in all types of clinical events. Moreover, associated benefits such as early
detection, high accuracy, and cost-efficiency are also anticipated to be the
growth inducing factors.
·
Books dominated the overall product segment
in terms of revenue share as of 2014 owing to the preference by clinicians and
healthcare professionals as a primary source of information pertaining to
adverse drug reactions. Online media is anticipated to be the fastest growing
segment with a CAGR of over 13.0 % during the forecast period owing to rising
inclination towards digitalized data.
·
Hospitals held the dominant share of
end-use segment as a consequence of low costs associated with hospital based
post-marketing pharmacovigilance surveillance. Research organizations segment
is anticipated to show significant growth rate in coming years owing to streamlining
of R&D in developing of new medicines and improving risk management through
early prognosis of ADRs.
·
The key players of post-marketing
pharmacovigilance and medical information market include Accenture Plc.,
Clinquest Group B.V., Cognizant Technology Solutions Corporation, Covance,
Inc., iMEDGlobal Corporation, inVentiv Health Clinical, Parexel International
Corporation, Pharmaceutical Product Development, Inc., PRA Health Sciences,
Inc., Quintiles, F. Hoffmann-La Roche Ltd., Sanofi Aventis, Synowledge LLC,
Wipro Ltd., ArisGlobal, Ergomed Plc. Rising strategic alliances and mergers
&acquisitions are also anticipated to drive market growth. For instance, in
January 2016, strategic collaboration of Parexel and Optum for reducingcosts
related to post-approval studies and spreading awareness among the population
base.
The
global post-marketing pharmacovigilance and medical information market size was
valued at USD 2.02 billion in 2014. Rising demand for new drug development
coupled with presence of technologically advanced, easily accessible medical
information system is expected to boost the market growth over the forecast
period.
As
per the ISMP (Institute for Safe Medication Practices), approximately two of
every three patients who visit a doctor leave with at least one prescription
drug. Drug consumption has increased substantially owing to rapidly growing
disease prevalence rates. Approximately 6.4 billion drugs were dispensed in the
U.S alone in 2014. Rise in the prevalence of chronic diseases such as
cardiovascular & respiratory disorders, oncology and diabetes have
increased the consumption of drugs worldwide.All the aforementioned factors are
attributing towards the post-marketing pharmacovigilance and medical
information market growth in near foreseeable future.
Furthermore,
increasing incidences of adverse drug reactions imposes a substantial burden on
healthcare systems and is one of the prominent reasons of morbidity in
developed countries. According to the ISMP, currently, more than 10,000 prescription
drugs and 300,000 over-the-counter (OTC) medications are available in the U.S.
It has also been stated that nearly 1.5 million preventable ADRs (Adverse Drug
Reactions) occur in the U.S. each year.Growing instances of ADRs resulting in
drug withdrawals is expected to drive market growth during the forecast period.
Have any Query? Ask our Experts:
Grand View Research has segmented the global
post-marketing pharmacovigilance and medical information market on the basis of
type, product, end-use:
Global post-marketing pharmacovigilance type outlook
(Revenue, USD Million, 2012 - 2022)
·
Spontaneous Reporting
·
Intensified ADR Reporting
·
Targeted Spontaneous Reporting
·
Cohort Event Monitoring
·
EHR Mining
Global post-marketing pharmacovigilance and medical
information product outlook(Revenue, USD Million, 2012 - 2022)
·
Books
·
Online Media
·
Journals
Global post-marketing pharmacovigilance and medical
information end-use outlook (Revenue, USD Million, 2012 - 2022)
·
Hospitals
·
Research Organizations
·
Others
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment